Frost.com - Healthcare Research

Home Healthcare Technology Innovations and Growth Opportunities

Wed, 10 Aug 2022 00:00:00 +0000

Hospitals have been the mainstay of providing care delivery to patients, including diagnostic services and therapeutic interventions. However, as a limited number of health professionals cater to multiple patients, caregivers are unable to dedicate sufficient time to each patient to understand their needs and effectively monitor their response to the treatment delivered to them, which impacts health outcomes. Furthermore, in-hospital care exposes patients to HAIs that can impact their well-being and cause a spike in the mortality rate. These limitations have necessitated the demand for home healthcare that provides greater convenience to patients and improves their health outcomes and reduces healthcare costs for providers. Typically, home healthcare involves medical care provided by physicians and other skilled medical professionals to patients outside the traditional healthcare environment (including hospitals) in the comfort of their homes. As home healthcare offers hospital-level diagnostic and treatment services to patients, mainly to address critical pain points such as reducing the incidence of hospital-acquired infections (HAIs), decreasing preventable hospital readmissions, and enabling effective care for patients, the model is attracting healthcare providers. This growth opportunity-technology (GO-TE) study highlights innovation in home healthcare technologies, including home care ventilators, home dialysis devices, at-home electrocardiograms, and home infusion devices. The market scope of this GO-TE study is global. It studies some of the pathbreaking innovators in this space and their technology readiness levels.

Innovations and Growth Opportunities in Medical Imaging, Surgical Robot and Digital Health

Fri, 29 Jul 2022 00:00:00 +0000

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) profiles a wide range of innovations from the advanced medical device and imaging industry. The issue includes advanced imaging technologies such as photon-counting computed tomography, portable wireless ultrasound, AI based ECG, and digital twin for surgery planning. Some of the advanced surgical robot innovations include hybrid surgical robot, ergonomic design and high definition visualization, endoscopic surgical robot. The AI enabled diagnostics such as AI enabled ophthalmic diagnostic platform, AI/ML enabled fracture detection, AI enabled post operative delirium are also included in this issue. These innovations portray the diversity in their technology readiness levels, indicating an immediate or potential market impact. The growth opportunities for all these advanced medical device technologies are also covered in this issue. The Advanced MedTech TOE analyzes and reports new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of wearables, implantable, diagnostics, surgical tools and instrumentation, image guided surgery, drug delivery, patient monitoring, digital health, and medical imaging. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Photon-counting Computed Tomography (CT) , High-resolution Imaging , Wireless Handheld Ultrasound, portable ultrasound, mobile medical imaging, surgical robot, robotic surgery, laparoscopy, AI, AI/ML, diabetic retinopathy, hemodialysis, home care, ECG, visual prosthesis, artificial vision, contactless monitoring, remote monitoring, endoscopic surgical robot, minimally invasive, ophthalmic diagnostic, Keratotomy Surgery Planning , Digital Twin, bone fracture, software as medical device, SAMD, Postoperative Delirium , health monitoring, Interstitial Fluid Diagnostic, Epifluidic Diagnostic, Pediatric Cystic Fibrosis.

Growth Opportunities in Synbio Tools For DNA Synthesis, Engineered Microbes, Microbiome Based Wellness Solutions and Targeted Drug Delivery

Fri, 22 Jul 2022 00:00:00 +0000

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on use of microbiome profiling for development of tests for women health. Innovations in the Synthetic Biology space, including advanced enzymatic DNA synthesis and engineered microbes for healthcare applications have been highlighted. Improvements in targeted drug delivery, and use of non invasive liquid biopsy for liver disease diagnosis has also been featured in this issue. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Synthetic biology, DNA synthesis, engineered microbes, gene circuits, microbiome, microbiome tests, next generation probiotics, sports nutrition, women wellness, microbial profiling, vaginal microbiome analysis, women health, bacterial robots, targeted drug delivery, liquid biopsy

Predictive Genetic Testing: Technology Landscape

Thu, 21 Jul 2022 00:00:00 +0000

Predictive genetic testing refers to the testing of genetic mutations and variations in an individual to predict the risk of disease susceptibility and the inheritance of Mendelian diseases and other complex diseases. Genomic analysis studies such as genome-wide association studies (GWAS), SNP arrays, and the WGS of select populations have helped to understand the impact of mutations and variants on health and disease risk; rising awareness and public/private initiatives for preventive healthcare are also driving market growth. Massively parallel NGS-based methods and advanced genomic and cytogenomic analysis tools are used in predictive genetic tests (PGTs) to analyze gene mutations, variants, and chromosomal aberrations, which can increase the susceptibility of a disease; PGTs are also being used to predict disease severity. The use of large-scale genomics data to develop population-based genomic studies for predictive and preventive health is also gaining traction, and several countries, including the United States and the United Kingdom, have carried out large-scale genomic studies to develop DNA repositories that can be used in preventative healthcare strategies. The key technologies used in genomic analysis include whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing (gene panels), and genotyping (SNP arrays, optical genome mapping), and each technology has its own advantages and disadvantages. Combining DNA analysis with microbiome DNA assessment and RNA analysis can improve the clinical utility of PGTs, and many research organizations and start-ups are focusing on combination-based tests to improve clinical utility for disease risk prediction. Although PGTs have been commercialized for more than 10 years, adoption continues to remain low. This is primarily due to the unclear clinical benefits of these genetic tests and the lack of involvement of health authorities and regulatory body oversight. The most widely used PGT for clinical purposes is hereditary cancer testing (HCT), where a multitude of genes are analyzed for inheritable cancer prediction. While BRCA1 and BRAC2 mutation testing has been used for breast cancer and ovarian cancer risk prediction, the discovery of new gene markers, variant interpretation tools, and the development of multiplexed assays of multigene panels will make this testing type more clinically relevant. The widespread utilization of PGTs can also foster an era of personalized medicine based on individual disease risk profiles. PGTs are also being increasingly developed for nonclinical purposes, and they are widely available in the direct-to-consumer (DTC) format where individual genomes are assessed to predict innate traits and improve overall health and wellness. This Frost & Sullivan research service discusses the importance of predictive genetic testing in disease susceptibility prediction, the discovery of novel disease biomarkers for drug discovery, pharmacogenomics, metabolism, nutrigenomic profiling, and well-being, among other topics. Several new companies have entered this market, and they are focused on reducing test costs and improving test sensitivity and accuracy. Collaborations are also on the rise, with pharmaceutical companies partnering with PGT developers and public healthcare systems engaging with multiple entities to work on genomic analysis to accelerate preventive health strategies at a national level. The deployment of advanced data analysis tools and data storage and management systems is also fostering the growth of PGTs.

Global Mammography Vendor Profiles and Growth Opportunities

Wed, 20 Jul 2022 00:00:00 +0000

This Frost & Sullivan study examines the role of artificial intelligence (AI) in the global mammography market. The high prevalence of breast cancer in women has increased the demand for breast cancer screening, which, in turn, heightened the focus on using AI-based solutions for mammography. AI solutions can reduce results variability among radiologists and improve breast cancer detection rates. They also play a pivotal role in decreasing radiologists workloads and boosting the affordability and accuracy of breast cancer screening programs. The study outlines the key trends emerging in the AI and mammography space and profiles notable providers and solutions in three core mammography functions: Image analysis, triage, and clinical decision support. The study also guides technology vendors in charting their strategic priorities and building new capabilities to capitalize on emerging growth opportunities in the mammography space.

Frost & Sullivan Global Cloud User Survey, Q4 2021

Fri, 15 Jul 2022 00:00:00 +0000

This research service presents the findings of the global cloud user survey conducted by Frost & Sullivan between October 2021 and November 2021 to derive insights on cloud adoption, deployment, and usage. The primary goal of this research is to analyze the cloud computing technology adoption trends among healthcare organizations, including top business strategic goals, preferred cloud deployment models, and information technology (IT), and identify the business challenges in cloud migration and cloud repatriation as well as the expansion opportunities for healthcare cloud providers. Patient demands for connected care, healthcare data interoperability, and virtual care technology such as telehealth and remote patient monitoring to enable provider-patient collaboration have led to a greater focus on the cloud in healthcare. The COVID-19 pandemic accelerated digitization in healthcare, resulting in a new era of technology adoption in the industry. The need for secured data storage and privacy had a positive impact on the healthcare cloud market, accelerating digitization and pushing healthcare organizations to adopt end-to-end hybrid cloud and multi-cloud strategies. The regional segmentation of this survey is as follows: North America (The United States and Canada) Latin America (Brazil and Mexico) Europe and the Middle East The Asia-Pacific--BEGIN PROMO--

Key Issues Addressed

What infrastructure options are healthcare organizations using and planning to add?
How do healthcare organizations decide whether to deploy an app in the public data center or the corporate data center?
What percentage of apps and data does the public cloud use?
What factors made healthcare organizations choose their primary cloud service provider?
Would healthcare organizations engage the services of a managed cloud service provider? Why?

Author: Rishi Pathak

United States Molecular Point-of-Care Testing Growth Opportunities

Thu, 14 Jul 2022 00:00:00 +0000

Rapid advancements in infectious disease diagnostics continue with novel identification methods and healthcare accessibility improvements. The shift from traditional testing to a more technologically empowered, consumer-centric testing encompasses the sample-in-answer-out approach of diagnostic testing that generates results in minutes or hours. Nucleic acid amplification technologies meeting the criteria for point of care or designated as moderately complex tests to detect single or multiple pathogens have transformed the requirements for test sensitivity, specificity, and turnaround time. A personalized medicine and treatment program that establishes clinical treatment plans for infectious diseases on a patient-by-patient basis is a hot topic of discussion in clinical microbiology and virology. Molecular diagnostic technologies, such as polymerase chain reaction and other nucleic acid-based amplification technologies, gradually replace or improve traditional laboratory techniques for pathogen identification through point-of-care tests. The driving force enabling this shift stems from the ability of point-of-care tests to detect microorganisms indicating possible poly-microbial infection. State-of-the-art molecular point-of-care testing for infectious diseases enables physicians to make early evidence-based treatment decisions. Many of these tests have received waiver from the Clinical Laboratory Improvement Amendments and are easy to use. The diagnostics industry is moving toward comprehensive syndromic tactics, simultaneously detecting multiple pathogens with overlapping clinical syndromes. The growing need for syndromic point-of-care testing propels leading companies in the in vitro diagnostics space to prioritize pipeline expansion and fortify their partnerships. With consumers increasingly monitoring their health and wellness, test developers will explore innovative methods to change the care delivery paradigm. The paradigm shift could create new channels to deliver consumer-grade offerings, expand access to high-quality laboratory testing, and empower individuals to take charge of their health and well-being. This Frost & Sullivan study sheds light on the US molecular point-of-care testing industry, identifying three key growth opportunities by assessing the industry s instruments/platforms, consumables (assays and kits), regulatory environment, emerging business models, and revenue forecasts. Analyst: Amartya Bose

Women s Health Solution Growth Opportunities

Thu, 14 Jul 2022 00:00:00 +0000

As the healthcare industry moves toward the ideas of personalized medicine and health equity, an important consideration in disease and treatment experiences is gender. While fine-tuning treatment paradigms for women will probably take decades, several areas of women s health are possible to address even today. This project focuses on 3 specific areas (maternal mortality and morbidity, menopausal care, and pelvic health) to highlight the progress being made in women s health solutions. Emerging and existing solutions serve only a small proportion of the total addressable market, indicating a large potential opportunity to serve the many women whose needs remain unaddressed. Frost & Sullivan has considered solutions that are available and in the development pipeline, as well as those that can indirectly address any of the issues. The study excludes from consideration basic telehealth services that do not incorporate technology-based solutions, and unregulated, consumer-oriented products and solutions such as the Apple Watch and Fitbit wearables. The project provides an overview of each area, highlights available and in-development solutions, offers snapshots of some of these solutions, spotlights notable vendors, and explores needs that remain unmet. The Growth Opportunity Universe provides several calls to action. Companies can leverage this information to build up an advantage in this industry. Author: Suchismita Das

Global Pharmaceutical Tracker, 2022

Wed, 13 Jul 2022 00:00:00 +0000

This research service offers comprehensive discussions about the key approvals, mergers and acquisitions, product licensing deals, and digital partnerships of the pharmaceutical industry in 2022. A renewed focus on operational excellence and digital transformation will push top-line pharmaceutical industry growth and drive strong partnerships with small and mid-size pharma and digital solution vendors. The digital implosion is transforming the pharma business model to achieve digital maturity. Big pharma is moving toward technology vendor partnerships to accelerate digitization and de-risk investments in in-house capabilities, platforms, and solutions. Diminishing R&D pipelines, stagnant productivity during the last 2 decades, and the disruption in clinical trials due to the pandemic have led to a surge in partnerships. Small and mid-sized companies will continue to attract big pharma and private equity (PE) firms. New modalities and technologies will remain attractive for licensing deals, giving biotech licensor candidates a higher chance of negotiating contract terms and up-front payments.

Growth Opportunities for Digital Biomarkers in Drug Development

Wed, 13 Jul 2022 00:00:00 +0000

Pharmaceutical companies spend billions of dollars in drug development because of expensive and time-consuming clinical trials, with a meager success rate. Frequent clinical visits, manual data processing, and a lack of consistent data on the effectiveness of the investigation of medical products contribute to their low success rate. Digital biomarkers derived from wearable sensors and advanced algorithms offer an opportunity to analyze the response of investigational medical products in clinical trials continuously and remotely. Digital biomarkers eliminate the need for frequent clinic visits to monitor the patient's health status. The halting of clinical trials because of the COVID-19 pandemic has fueled digital biomarker adoption for remote patient monitoring in clinical practices and clinical trials. Remote patient monitoring is imperative for pharmaceutical companies to conduct efficient clinical trials, save costs, and decide on proceeding with or discontinuing an investigational drug. Efforts are underway by market participants to transform digital biomarkers into digital measurements or endpoints in clinical trials. Digital biomarkers are instrumental in assessing the efficacy and safety of the therapy in DCTs and timely patient recruitment. Digital biomarkers offer an opportunity for pharmaceutical companies to advance research in complex diseases, such as AD and PD, and to find novel biomarkers that demonstrate the effectiveness of an investigational drug on a patient s disease condition in clinical trials. The study focuses on 3 major therapy areas, neurology, oncology, and cardiology, which digital biomarkers impact.

Global Ultrasound Growth Opportunities

Wed, 6 Jul 2022 00:00:00 +0000

New solutions include the integration of tools such as AI, which streamlines processes by automating tasks and offering guidance to operators on the use of ultrasound equipment. These solutions also reduce variabilities across devices and operators and improve the early diagnosis of chronic diseases. The study will help ultrasound equipment providers understand the key trends emerging in the market (across different healthcare domains as well as geographic regions). It provides an overview of vendors offering ultrasound solutions for several areas of application, including general imaging, cardiology, obstetrics and gynecology, and vascular and anesthesiology, and the equipment is segmented into 3 types, based on portability, that is, cart-based, hand-carried, and handheld ultrasound devices. The research service also offers guidance for ultrasound vendors in terms of charting strategic priorities and building new capabilities to capitalize on the emerging growth opportunities in the ultrasound market.--BEGIN PROMO--

Research Scope

In this research service, Frost & Sullivan examines the expansion of the use-cases of ultrasound for different disease areas and diagnostics as well as treatment. The low cost and the ultraportability of these devices and the high-quality images they offer have expanded their areas of application. In addition, the noninvasiveness of ultrasound devices allows them to be used in complex processes and to reach parts of the human body that could not be reached earlier.

In Vitro Diagnostic eCommerce Business Models Growth Opportunities

Tue, 5 Jul 2022 00:00:00 +0000

Diagnostics are central to healthcare, but not accessible to all. A 2020 Lancet study states that 47% of the global population has little to no access to accurate diagnostics, emphasizing the need for equitable distribution across geographies and containing procurement costs. The COVID-19 pandemic increased demand for personal protective equipment, consumables for molecular diagnostics, vaccines, and POCT testing for SARS-Cov2. However, serious glitches in supply and logistics due to poor procurement strategies led to manufacturing delays and a surge in diagnostics and healthcare costs. Vendors of R&D prototyping, small-batch manufacturing services, and niche testing labs recorded the largest revenue drop across the value chain. The coronavirus also accelerated healthcare digitalization, including in vitro diagnostics (IVD). Engineering and technological innovations present opportunities to create new eCommerce platform solutions in the diagnostics segment, emphasizing global connectivity, transparency, access, scalability, and cost efficiencies. These features reduce the gaps in the IVD industry, improve access, and democratize diagnostics to empower providers, payers, and patients. Lessons learned from the pandemic in 2020 and 2021 serve as the building blocks to strengthen healthcare systems, primarily timely health service delivery, attention to the healthcare workforce, need for robust health information systems, access to diagnostics (analogous to essential medicines), efficient supply chain for procurement and supplies, and seamless communication and interconnectedness, financing, leadership, and governance. eCommerce marketplaces for healthcare and IVD provide an opportunity to buy, sell, lease, market, and procure diagnostic products and service information on any internet device, such as the computer (web-based) or mobile (mCommerce). Pharmaceuticals, biotech companies, contract research organizations, hospitals, clinics, universities, laboratories, government, and customers can use these technology platforms to access the global ecosystem. While technology infrastructure within eCommerce is evolving, essential technologies enabling healthcare transactions include EDI, bar codes, cloud, product data exchange, and electronic forms. This study assesses the eCommerce business potential across sectors, creating resilient healthcare and diagnostic market opportunities for R&D, manufacturing, and supply chain functions. It explores other scalable, cost-efficient business opportunities with new B2B products, customized outsourcing services, and technology-enabled tools for efficiency and ease of operations. The IVD market is buoyant due to the soaring demand for products, molecular diagnostics, immunoassays, and POCT in chronic diseases. The rise in consumerization, telehealth, and ePharmacy also push it toward further digitalization with advanced artificial intelligence, machine learning, and the internet of things technologies. The study also examines the competitive environment, strategies, market models, and use cases for success in the IVD eCommerce platform industry. Author: Tejashri Manish Khadilkar

Global Cardiac Monitoring Devices Growth Opportunities

Mon, 4 Jul 2022 00:00:00 +0000

This research service provides an overview of the global cardiac monitoring devices market. The geographical scope of this global study is North America (NA), Europe, and Asia-Pacific (APAC). It offers a detailed analysis of market sizing, trends, competitive landscape, future market outlook by region, and growth opportunities. The market is segmented into Resting ECG Systems, Stress ECG Systems, Holter Monitors, Cardiac Event Monitors, and Medical Grade Wearables. This study focuses on technology, connectivity, continuous monitoring, and new pathways for cardiac monitoring. The competitive analysis includes company market shares for traditional cardiac monitoring devices and wearables at the global level. Market sizing includes historical and forecast revenue and volume data by region and segment analysis. The study focuses on digital technology adoption, such as RPM, AI, ML, and predictive analytics, and discusses companies operating and providing services in this space. In addition, home healthcare and 5G adoption for connected devices are discussed. Author: Vittal Bhaskar Rao

Global Neonatal Care Devices Growth Opportunities

Mon, 4 Jul 2022 00:00:00 +0000

The neonatal care industry is shifting its focus to providing family-centric and developmental care to neonates. Neonatal Intensive Care Units (NICUs) are looking at reducing neonatal stress, such as noise and intense light, to provide complete holistic care for neonates. Wireless capabilities and portability are the new features in neonatal care devices and are giving a new direction to classic neonatal care devices. The COVID-19 pandemic resulted in a shortage of healthcare resources, including that of healthcare staff. NICUs are also facing severe staff shortages. Thus, neonatal care products supporting automation and enhancing the workflow, such as AI-based predictive monitoring and workflow automation technologies, will be attractive for organizations in the near term. The global neonatal care devices market is segmented into thermoregulation devices, jaundice management devices, neonatal monitoring units, and respiratory assistance devices. Neonatal thermoregulation devices and ventilators are high-value segments. They generated the highest revenue among all neonatal care devices. Thermoregulation devices, including incubators and warmers, are updated to provide family-centric features and reduce neonatal stress. The adoption of thermoregulation devices is growing owing to innovations in incubators and warmers focusing on family-centric and developmental care. Jaundice management is the smallest segment. Phototherapy units used in jaundice management are highly commoditized. They are available through multiple local participants in South Asian countries. Additionally, various portable devices (e.g., phototherapy blankets) are supporting the growth of phototherapy units. North America is the largest market for neonatal care devices and will continue to be in the lead. Asia-Pacific is the fastest-growing market owing to the emergence of local participants providing affordable solutions. The Rest of the World market is also estimated to be lucrative due to the increasing adoption of neonatal care devices in Latin America, the Middle East, and Africa. Affordability is low in South Asia and Africa, making access to neonatal care devices difficult. Various start-ups that have emerged in the last few years provide low-cost solutions in these regions. Moreover, various initiatives undertaken by public and private organizations are increasing neonatal care device adoption in low- and middle-income economies.

INNOVATIONS AND GROWTH OPPORTUNITIES IN NOVEL DIAGNOSTICS AND MONITORING SOLUTIONS, ROBOTIC SURGICAL SYSTEMS, AI ENABLED DEVICES

Fri, 1 Jul 2022 00:00:00 +0000

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) profiles a wide range of innovations from the advanced medical device and imaging industry. This issue includes novel diagnostic and monitoring solutions such as COVID detection, skin patch for patient monitoring, wireless monitoring in hospitals and many more . Some of the other advanced medical device innovations covered in the report include robotic surgical systems such as single port surgery and Vitreoretinal surgeries; AI based personalized diabetes management and AI based respiratory monitoring. These innovations portray the diversity in their technology readiness levels, indicating an immediate or potential market impact. The growth opportunities for all these advanced medical device technologies are also covered in this issue. The Advanced MedTech TOE analyzes and reports new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of wearables, implantable, diagnostics, surgical tools and instrumentation, image guided surgery, drug delivery, patient monitoring, digital health, and medical imaging. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: COVID, AI, skin patch, EEG, surgical robot, robotic surgery, Vitreoretinal, point of care, breath test, lung function, respiratory, diabetes, AI, refrigeration device, vaccine transport, wearable, neurological diagnosis, sleep monitoring

Digital CX Investments Driven by the Quadruple Aim in Healthcare, Global, 2022

Wed, 29 Jun 2022 00:00:00 +0000

The healthcare industry was hit hard by the pandemic as it tackled the toughest of challenges around the globe- slowing down the virus, managing hospital capacity, keeping its staff safe, and ensuring patient privacy and confidentiality. Contact centers were busy far beyond capacity, driving organizations of all sizes to accelerate investments in self-service channels and the cloud. The great resignation forced providers to invest in improving the employee experience. This study uses an integrated 360-degree research methodology to provide insights from end-user organizations, healthcare experts and IT analysts. Frost & Sullivan surveyed decision-makers in the healthcare industry to discover investment plans over the next year. Not surprisingly, the pandemic had a significant impact on customer experience (CX). Key insights from the survey revealed: - Traditional pain points for contact centers (such as being seen as cost centers or operating as silos) faded away in importance as healthcare facilities were forced to change to deal with the exponential growth in communications with patients. - Providers are evaluating the optimal balance of work-at-home (WAHA), hybrid, and on-site workers. Key considerations include ensuring the stability, reliability, and security of network operations; training agents/supervisors on new applications; and persuading customers to use new interaction channels. - Healthcare organizations are moving to the cloud to benefit from new technology, flexibility, and reduced upfront costs. - Providers are improving employee retention by providing flexible work locations/remote work options, creating a fun environment/corporate culture, empowering employees with solutions that allow them to make their own/better decisions, implementing a career growth strategy, and improving employee training & development programs. - Respondents included IT decision-makers from hospitals, clinics, medical practices, health systems, health services, residential nursing, and physical therapy organizations. It explores their plans to improve CX expectations as the world recovers from the pandemic. A top priority is improving the employee experience. Channels covered: voice, email/web form, social media messaging apps, social media apps, mobile apps, SMS, Chat with live agents, virtual agents, video chat, video teller/kiosk, and IVR. Technologies covered: conversational AI & virtual assistants/bots, quality monitoring, collaboration tools, performance management, flexible APIs/CPaaS, eLearning for agents, proactive customer care, gamification, and augmented reality. This study is valuable for solution providers to better understand what each industry seeks in delivering excellent CX and healthcare organizations to benchmark themselves against the competition and other industries. Author: Alpa Shah

Micro- and Nanofluidic Technology Innovations for Infectious Disease Control and Management

Thu, 23 Jun 2022 00:00:00 +0000

The rise in both global population and travel is contributing to the increase in spread of infectious diseases. Rapid and accurate identification of the infectious pathogens are imperative for timely intervention, better patient outcomes, and control and management of the spread of the infection. Conventional infectious disease diagnoses are performed in centralized labs; they have a long turnaround time and require expertise. Microfluidics-based infectious disease diagnostics, on the other hand, can enable multiplexed pathogen detection, rapid turnaround, and results at the point of care; they help healthcare providers take quick clinical decisions on treatment or isolation, and enable a lower rate of incidence. In this report, the microfluidics-based infectious disease diagnostic innovations have been segmented by the property/phenomenon exploited for the isolation or identification. This Frost & Sullivan research service analyzes the drawbacks of conventional infectious disease diagnosis and the benefits of employing microfluidics in infectious disease diagnostics. It also covers growth drivers and the restraints in the micro-/nanofluidic infectious disease diagnostics industry, emerging microfluidic technologies, and companies to action. Technology adoption trends, innovation indicators, and the commercialization voids in the micro-/nanofluidic infectious disease diagnostics are also analyzed. Growth opportunities offered by advanced loop-mediated isothermal amplification platforms, rapid antimicrobial resistance detection platforms, and advanced infectious pathogen biosensors are also discussed. The study also includes an IP landscape analysis of the patents filed over the last 6 years, critical success factors and strategic recommendations.--BEGIN PROMO--

The spread of infectious diseases is increasing with the rise in global population and global travel. Rapid and accurate identification of the infectious pathogens are imperative for timely interventions enabling better patient outcomes and efficient control and management of the spread of the infection. Conventional infectious disease diagnosis are performed in centralized labs. They have a long turnaround time and requires expertise. Microfluidics-based infectious disease diagnostics can enable multiplexed pathogen detection, rapid turnaround and results at the point of care. It allows healthcare providers to take quick clinical decisions on treatment or isolation, and prevent endemic or epidemic or pandemic. In this report, the microfluidic-based infectious disease diagnostic innovations have been segmented based on the property/phenomena exploited for the isolation or identification. This Frost & Sullivan research service analyzes the drawbacks of conventional infectious disease diagnosis and the benefits of employing microfluidics in infectious disease diagnostics. The growth drivers and the restraints in the micro/nanofluidic infectious disease diagnostics industry are detailed. The emerging microfluidic technologies enabling infectious disease diagnosis and the companies to action are explored. The technology adoption trends, innovation indicators and the commercialization voids in the micro/nanofluidic infectious disease diagnostics are put forth. Growth opportunities offered by advanced loop-mediated isothermal amplification platforms, rapid antimicrobial resistance detection platforms and advanced infectious pathogen biosensors are discussed. The study also includes an IP landscape analysis of the patents filed over the past 6 years. Critical success factors and strategic recommendations are also discussed.

Global Operating Room Devices and Solutions Growth Opportunities

Wed, 22 Jun 2022 00:00:00 +0000

Hospitals are under extreme pressure to reduce costs and increase profits. Considering today s uncertain regulatory climate and challenging economic environment, medical device companies are challenged to provide products and services to hospitals at an affordable cost. The operating room (OR) offers many opportunities to do so. ORs drive approximately 60% of revenue in the average hospital. The most critical issues in an OR, however, involve finding new methods to reduce human error and improving the efficiency and quality of surgical care. Technology is now available to help hospitals reduce surgical risks and maximize their return on OR investments. As such, the opportunities for medtech players continue to grow as mergers and acquisitions increase. Venture capitalists are shifting their focus to invest in early-stage companies that develop innovative medical technologies, which means emerging medical device companies need to think outside the box by accomplishing more with less expenditure. Apart from offering compatibility , OR vendors will need to focus on future-proofing their devices and solutions by offering long-term contracts that will enable them to retain clients and deliver upgraded versions of their solutions. This will include compatibility in terms of dexterity, connectivity, data capture, and supporting capabilities for virtual reality (VR), augmented reality (AR), and mixed reality (MR) for the OR. OR products and solutions are transitioning from simple boxes to technology-fueled, integrated services, with advancements in minimally invasive surgery (MIS) to minimize hospital stays. Offering a full range of OR products with bundling decreases the average sales price for components and solidifies market share. As hospitals look to invest in solutions that integrate and collaborate multidisciplinary units and devices for optimal resource and space utilization, companies are transitioning their offerings from OR products to OR solutions and catering to low-cost settings. This study focuses on 2 market segments: OR workflow solutions and OR surgical workplace devices. Factors that will influence average selling prices through the forecast period (2022 2026) include intense competition from low-cost vendors, price pressure on manufacturers, and system upgrades to digital or integrated platforms. However, manufacturers will provide additional services to healthcare facilities as a part of long-term contracts. Those services will include: consultation on workflow management; coordination of production, inventory, location, and transportation in a supply chain; use of data analytics to predict demand and streamline order; and collaboration with hospitals and centers with larger surgery volumes. Author: Bejoy Daniel

Growth Opportunities in AI for Drug Target Discovery and Validation

Wed, 22 Jun 2022 00:00:00 +0000

A major challenge in drug discovery is the limited number of gene targets that can be targeted for the development of a drug molecule. Only close to 400 genes are proven targets for US FDA-approved drugs. 80% of human genes are unexplored as targets, and some are considered undruggable. The identification and the selection of novel drug targets (proteins/genes) have remained major challenges in drug discovery as the identification of a molecular target requires assessment of genomics, proteomics, and in vitro and in vivo experimental data interpretation. The challenge lies in the lack of technology to break down complex biological networks and map them thoroughly. Scientists find it difficult to mine through large volumes of biological data and draw meaningful insight from them. The identification of novel drug targets will open up opportunities for the development of new drug molecules and the provision of treatment options for diseases with limited/no options. The identification of novel drug targets is built on the hypothesis developed by researchers, which is based on scientific literature and available databases, followed by experimental data that supports the hypothesis. Experimental approaches for drug target identification involve a series of experiments and the assessment of the modulations caused at the drug target site. Most hypotheses do not yield the desired outcomes and provide negative results. Carrying out in vitro studies and developing multiple assays for target identification are lengthy and time-consuming processes that involve high costs to set up experiments. Moreover, the manual interpretation of vast amounts of biological data is challenging and time consuming. Over the years, significant advances have been made to identify novel drug targets using different approaches, including advanced bioinformatics tools and automated experimental designs, but these have failed to provide fruitful outcomes and led to financial burdens on drug developers. Nevertheless, researchers continue to develop platforms that aid successful novel target discovery. Today, with the help of AI and ML algorithms, it is possible to identify new drug targets; moreover, developments in new modalities enable the targeting of undruggable targets, thereby increasing the success rate of drug discovery. An AI algorithm can predict a potential target through its scoring mechanism based on the data collected from gene expressions, protein-protein interactions, clinical trials, and disease biologies. The score provided by the AI algorithms is responsible for the prioritization of the drug target. High-score targets are more likely to be considered for further experimental validation. The most extensively used deep learning algorithms are convolution neural networks (CNNs), recurrent neural networks, deep belief networks, and deep neural networks. Pharmaceutical companies are beginning to understand the value of AI due to its increasing adoption across several industries. AI algorithms are being trained using advanced biology and chemistry data, making them more efficient in terms of making accurate decisions and identifying missing links. AI in drug discovery is creating a new era of virtual drug discovery labs that are capable of both novel drug target identification and drug molecule discovery. Pharmaceutical companies are making significant investments in collaborative programs or licensing programs in AI platforms to identify novel therapeutic drugs for various diseases.

GROWTH OPPORTUNITIES IN SYNTHETIC BIOLOGY, LOGIC GATED THERAPIES, RAPID MOLECULAR DIAGNOSTICS AND PEPTIDE SYNTHESIS PLATFORMS

Fri, 17 Jun 2022 00:00:00 +0000

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on synthetic biology innovations around low cost gene synthesis and deployment of gene circuits for drug discovery and in therapies. Cell and gene therapies using logic gated circuits, along with early stage developers of gene circuits for drug discovery applications are covered. In addition advanced peptide design platforms and high throughput DNA synthesis platform has been covered. A rapid and sensitive molecular diagnostic for scalable Covid-19 testing, which can be adapted at PoC has also been discussed. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: CAR-T cell therapy, cancer immunotherapy, gene circuits, synthetic biology, drug discovery , small molecules, kinase inhibitors, cancer therapeutics, gene therapy, hematology, sickle cell disease, antibody drug conjugate (ADC), antibodies, tumor microenvironment, targeted cancer therapy, microbiome therapeutics, genetic testing, molecular diagnostics, rapid PCR, logic gated therapy, diagnostics, peptide synthesis, DNA synthesis, peptide design, AI, synthetic biotics, engineered microbes.

US Health Equity Growth Opportunities

Thu, 16 Jun 2022 00:00:00 +0000

Health equity is achieved when all sections of the population have attained their full potential for health and well-being, regardless of cultural background or socioeconomic status. Inequities resulting from differences in health and overall living conditions need to be identified and removed to realize health equity. Monitoring health inequity parameters is an important part of the health information system (HIS). Inequity monitoring entails collecting and disaggregating data (by age, sex, education, income, disability, and other factors), analyzing the information, and reporting the findings. The United States, with its well-established digital health infrastructure, has a significant advantage in ensuring health equity for its population. In this study, Frost & Sullivan identifies the segments that are crucial to achieving health equity. The study also identifies the main barriers to achieving health equity and the key solutions in the market that can address health gaps. A vendor landscape analysis and prevalent business models have also been provided. The study also takes a detailed look at the key regulatory policies being implemented by the government and identifies the growth opportunities emerging in the United States from the drive to achieve health equity for the population. Author: Chandni Mathur